Briacell Therapeutics Corp. (BCTX)
Last updated: 2026-11-05 17:54:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Briacell Therapeutics Corp. (BCTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.15, with a market capitalization of $26.28M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.60 to $13.09. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$26.28M | |
$3.32 | |
$1,870.50 | |
$2.60 | |
$3.19 | |
49.76K | |
262.90K | |
-- | |
$13.09 | |
$2.60 | |
-- | |
-- |
Briacell Therapeutics Corp. (BCTX) Stock Price Today
Briacell Therapeutics Corp. (BCTX) is currently trading at $3.15 as of 2026-11-05 17:53:00, down 1.16% ($0.04) from the previous close of $3.19
During today's regular trading session, BCTX has traded between $2.60 and $1,870.50, with a trading volume of 49.76K shares. The current price is near the lower end of today's range.
Briacell Therapeutics Corp. (BCTX) 7-Day Stock Price Change
Over the past seven days, Briacell Therapeutics Corp. (BCTX) moved from $3.56 to $3.15, representing a decline of 11.43% ($0.41).
The stock traded between $2.95 and $3.67 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 66.19 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
BCTX 52-Week Price Position
Position in Range: 5.3%
BCTX is currently trading at $3.15, placing it 5.3% of the way from its 52-week low of $2.60 to its 52-week high of $13.09. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Briacell Therapeutics Corp. (BCTX)?
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
Briacell Therapeutics Corp. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 31 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Briacell Therapeutics Corp. (BCTX) Stock on MEXC
Eligible investors can buy real shares of Briacell Therapeutics Corp. (BCTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Briacell Therapeutics Corp. (BCTX) stock price today?
2.Is BCTX stock going up or down today?
3.What is BCTX pre-market price?
4.What is BCTX after-hours price?
5.Is BCTX stock trading now?
6.Where does BCTX sit relative to its 52-week high and low?
7.What sector is Briacell Therapeutics Corp. in?
8.What is Briacell Therapeutics Corp.'s market capitalization and where is it listed?
9.How is BCTX valued in terms of P/E ratio and EPS?
10.Does Briacell Therapeutics Corp. pay a dividend?
Explore More US Stocks
Search Stocks
BCTX Stock Calculator
Estimate the value between BCTX shares and USD.
BCTX Shares to USD
1.00 BCTX shares = 3.153 USD
Calculations are estimates based on the latest available price and are for reference only.


